| 30389923 |
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
Vellano, CP,
Scott, KL,
Ju, Z,
Jeong, KJ,
Shao, SH,
Leonard, PG,
Woessner, R,
Mills, GB,
Sahni, N,
Ip, CKM,
Hua, X,
Ng, PKS
|
Nat Commun |
2018 |
| 22665524 |
Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors
Fletcher, JA,
Mariño-Enríquez, A,
Heinrich, MC,
Donsky, RS,
Presnell, A,
Griffith, DJ,
McKinley, A,
Liang, CW,
Patterson, J,
Taguchi, T
|
Mol. Cancer Ther. |
2012 |
| 31085175 |
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Hood, MM,
Gupta, A,
Su, Y,
Ensinger, CL,
Caldwell, TM,
Bulfer, SL,
Heinrich, MC,
Al-Ani, G,
Ahn, YM,
Patt, WC,
Janku, F,
Turner, BA,
Ruiz-Soto, R,
Leary, CB,
Abdul Razak, AR,
Yates, K,
Town, A,
Rosen, O,
Wise, SC,
Vogeti, L,
Telikepalli, H,
Rutkoski, TJ,
Vogeti, S,
Smith, BD,
Flynn, DL,
Chun, L,
Lu, WP,
Kaufman, MD,
McKinley, A
|
Cancer Cell |
2019 |
